AIMS/HYPOTHESIS: In healthy normolipidaemic and normoglycaemic control subjects, HDL are able to reverse the inhibition of vasodilation that is induced by oxidised LDL. In type 2 diabetic patients, HDL are glycated and more triglyceride-rich than in control subjects. These alterations are likely to modify the capacity of HDL to reverse the inhibition of vasodilation induced by oxidised LDL. SUBJECTS AND METHODS: Using rabbit aorta rings, we compared the ability of HDL from 16 type 2 diabetic patients and 13 control subjects to suppress the inhibition of vasodilation that is induced by oxidised LDL. RESULTS: Oxidised LDL inhibited endothelium-dependent vasodilation (maximal relaxation [Emax] = 58.2+/-14.6 vs 99.3+/-5.2% for incubation without any lipoprotein, p < 0.0001). HDL from control subjects significantly reduced the inhibitory effect of oxidised LDL on vasodilatation (Emax = 77.6+/-12.9 vs 59.5+/-7.7%, p < 0.001), whereas HDL from type 2 diabetic patients had no effect (Emax = 52.4+/-20.4 vs 57.2+/-18.7%, NS). HDL triglyceride content was significantly higher in type 2 diabetic patients than in control subjects (5.3+/-2.2 vs 3.1+/-1.4%, p < 0.01) and was highly inversely correlated to Emax for oxidised LDL+HDL in type 2 diabetic patients (r = -0.71, p < 0.005). CONCLUSIONS/ INTERPRETATION: In type 2 diabetes mellitus, the ability of HDL to counteract the inhibition of endothelium-dependent vasorelaxation induced by oxidised LDL is impaired and is inversely correlated with HDL triglyceride content. These findings suggest that HDL are less atheroprotective in type 2 diabetic patients than in control subjects.
AIMS/HYPOTHESIS: In healthy normolipidaemic and normoglycaemic control subjects, HDL are able to reverse the inhibition of vasodilation that is induced by oxidised LDL. In type 2 diabeticpatients, HDL are glycated and more triglyceride-rich than in control subjects. These alterations are likely to modify the capacity of HDL to reverse the inhibition of vasodilation induced by oxidised LDL. SUBJECTS AND METHODS: Using rabbit aorta rings, we compared the ability of HDL from 16 type 2 diabeticpatients and 13 control subjects to suppress the inhibition of vasodilation that is induced by oxidised LDL. RESULTS: Oxidised LDL inhibited endothelium-dependent vasodilation (maximal relaxation [Emax] = 58.2+/-14.6 vs 99.3+/-5.2% for incubation without any lipoprotein, p < 0.0001). HDL from control subjects significantly reduced the inhibitory effect of oxidised LDL on vasodilatation (Emax = 77.6+/-12.9 vs 59.5+/-7.7%, p < 0.001), whereas HDL from type 2 diabeticpatients had no effect (Emax = 52.4+/-20.4 vs 57.2+/-18.7%, NS). HDL triglyceride content was significantly higher in type 2 diabeticpatients than in control subjects (5.3+/-2.2 vs 3.1+/-1.4%, p < 0.01) and was highly inversely correlated to Emax for oxidised LDL+HDL in type 2 diabeticpatients (r = -0.71, p < 0.005). CONCLUSIONS/ INTERPRETATION: In type 2 diabetes mellitus, the ability of HDL to counteract the inhibition of endothelium-dependent vasorelaxation induced by oxidised LDL is impaired and is inversely correlated with HDL triglyceride content. These findings suggest that HDL are less atheroprotective in type 2 diabeticpatients than in control subjects.
Authors: E Nobécourt; S Jacqueminet; B Hansel; S Chantepie; A Grimaldi; M J Chapman; A Kontush Journal: Diabetologia Date: 2005-02-24 Impact factor: 10.122
Authors: Lukas E Spieker; Isabella Sudano; David Hürlimann; Peter G Lerch; Markus G Lang; Christian Binggeli; Roberto Corti; Frank Ruschitzka; Thomas F Lüscher; Georg Noll Journal: Circulation Date: 2002-03-26 Impact factor: 29.690
Authors: Brian G Drew; Noel H Fidge; Gabrielle Gallon-Beaumier; Bruce E Kemp; Bronwyn A Kingwell Journal: Proc Natl Acad Sci U S A Date: 2004-04-23 Impact factor: 11.205
Authors: A D Watson; M Navab; S Y Hama; A Sevanian; S M Prescott; D M Stafforini; T M McIntyre; B N Du; A M Fogelman; J A Berliner Journal: J Clin Invest Date: 1995-02 Impact factor: 14.808
Authors: Sonika Saddar; Véronique Carriere; Wan-Ru Lee; Keiji Tanigaki; Ivan S Yuhanna; Sajesh Parathath; Etienne Morel; Manya Warrier; Janet K Sawyer; Robert D Gerard; Ryan E Temel; J Mark Brown; Margery Connelly; Chieko Mineo; Philip W Shaul Journal: Circ Res Date: 2012-09-28 Impact factor: 17.367
Authors: J F Martín-Rodríguez; A Cervera-Barajas; A Madrazo-Atutxa; P P García-Luna; J L Pereira; J Castro-Luque; A León-Justel; S Morales-Conde; J R Castillo; A Leal-Cerro; D A Cano Journal: Int J Obes (Lond) Date: 2014-01-28 Impact factor: 5.095
Authors: Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb Journal: Nat Rev Cardiol Date: 2015-09-01 Impact factor: 32.419
Authors: Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman Journal: Diabetes Date: 2009-12 Impact factor: 9.461